Bristol-Myers Squibb to Acquire Adnexus Therapeutics
Bristol-Myers Squibb (Princeton, NJ) will acquire privately held Adnexus Therapeutics (Waltham, MA), the developer of a new therapeutic class of biologics called Adnectins.
Bristol-Myers Squibb (Princeton, NJ) will acquire privately held Adnexus Therapeutics (Waltham, MA), the developer of a new therapeutic class of biologics called Adnectins. The acquisition of Adnexus will help advance Bristol-Myers Squibb’s biologics strategy across multiple therapeutic areas and includes a Phase 1 oncology biologic, Angiocept. Adnexus Therapeutics will become a subsidiary of Bristol-Myers Squibb and remain based in Waltham, MA.
Under the terms of the agreement, Bristol-Myers Squibb will acquire all of Adnexus’ issued and outstanding shares of capital stock and stock equivalents in an all-cash transaction for a gross purchase price of $430 million. The closing of the transaction is subject to customary regulatory approvals.
Adnectins are a proprietary class of targeted biologics developed by Adnexus. Angiocept is an Adnectin designed to be an anti-angiogenic drug and is currently in Phase 1 development.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
